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Correspondence Prevalence of Peripheral Artery Disease by
Abnormal Ankle-Brachial Index in Atrial Fibrillation
Implications for Risk and TherapyTo the Editor: Nonvalvular atrial fibrillation (NVAF) is the most
common sustained arrhythmia encountered in clinical practice and
is associated with a 5-fold increased risk for stroke (1).
Moreover, patients with NVAF often suffer from atherosclerotic
complications such as acute myocardial infarction (AMI) (2).
Peripheral artery disease (PAD) is an established marker of systemic
atherosclerosis but its prevalence in NVAF is still unclear. We
reasoned that inclusion of ankle-brachial index (ABI), which is an
established tool for diagnosis of PAD (3), in the CHA2DS2-VASc
(4) score would better define the prevalence of vascular disease.
Toaddress this issue, the ItalianSociety of InternalMedicine (SIMI)
established an Italian registry documenting ABI in NVAF patients.
The Atrial Fibrillation Registry for the ARAPACIS (Ankle-
brachial Index Prevalence Assessment: Collaborative Italian Study)
study is an independent research project involving all Regional
Councils of SIMI. The first objective of the study was to estimate
the prevalence of ABI 0.90 in NVAF patients.
Consecutive patients with NVAF referred to internal medicine
wards were eligible for the enrollment. Enrollment started in
October 2010 and continued until October 30, 2012. Patients were
enrolled if they were 18 years or older and had a diagnosis of
NVAF, recording during the qualifying admission/consultation or
in the preceding 12 months, and if it was possible to obtain the
ABI measurement. Exclusion criteria included the following:
acquired or congenital valvular AF, active cancer, disease with life
expectancy <3 years, hyperthyroidism and pregnancy.
We initially planned to include 3,000 patients. The Data and
Safety Monitoring Board (Online Appendix) decided to perform an
interim analysis to assess the prevalence of ABI in the enrolled
populationsdas a higher than expected prevalence of low ABI was
detecteddand decided to interrupt the patients’ enrollment. The
sample size was amended as follows: a sample of 2,027 patients leads
to the expected prevalence of 21% with a 95% confidence interval
width of 3.5% (StataCorp LP, College Station, Texas).
Among the 2,027 NVAF patients included in the study, hyper-
tension was detected in 83%, diabetes mellitus in 23%, dyslipidemia
in 39%, metabolic syndrome in 29%, and smoking in 15%. At least 1
atherosclerotic risk factor was detected in 90% of patients.
The NVAF population was at high risk for stroke, with only
18% having a CHA2DS2-VASc score of 0 to 1, while 82% had
a risk 2. Despite this, 16% were untreated with any antith-
rombotic drug, 19% were treated with antiplatelet drugs (APs), and
61% with oral anticoagulants (OAC); 4% of patients were treated
with both APs and OAC.
Among the AF population, 428 patients (21%) had ABI 0.90
compared with 1,381 patients, who had an ABI of 0.91 to 1.39
(69%); 204 patients (10%) had ABI 1.40 (Fig. 1). ABI recorded
only in 1 leg was excluded from the analysis (n ¼ 14). ABI 0.90progressively increased from paroxysmal to permanent NVAF (18%,
21%, 24%; p ¼ 0.0315).
NVAF patients with ABI 0.90 were more likely to be hyper-
tensive (88% vs. 82%; p ¼ 0.032), diabetic (34% vs. 20%; p <
0.0001), or smokers (20% vs. 14%; p ¼ 0.0008), or to have experi-
enced transient ischemic attack or stroke (17% vs. 10%; p < 0.001).
NVAF patients with ABI 0.90 had a higher percentage of
CHA2DS2-VASc score 2 compared with those with ABI >0.90
(93% vs. 82%; p < 0.0001).
Logistic regression analysis demonstrated that ABI 0.90 was
significantly associated with a smoking habit (odds ratio [OR]:
1.99; 95% confidence interval [CI]: 1.48 to 2.66; p < 0.0001),
diabetes (OR: 1.93; 95% CI: 1.51 to 2.46; p < 0.0001), age class 65
to 74 years (OR: 2.05; 95% CI: 1.40 to 3.07; p < 0.0001), age
class 75 years (OR: 3.12; 95% CI: 2.16 to 4.61; p < 0.0001),
and history of previous transient ischemic attack/stroke (OR: 1.64;
95% CI: 1.20 to 2.24; p ¼ 0.002).
Vascular disease, as assessed by the history elements of
CHA2DS2VASc score, was recorded in 17.3% of patients; inclu-
sion of ABI 0.90 in the definition of vascular disease yielded
a total prevalence of 33%. A higher prevalence of vascular disease
was detected if ABI 0.90 was included in the CHA2DS2VASc
score (Fig. 1). CHA2DS2VASc including ABI 0.90 was more
associated with previous stroke (43%; OR: 1.85; 95% CI: 1.41 to
2.44; p < 0.0001) compared to CHA2DS2VASc with ABI 0.91 to
1.39 (23%; OR: 1.52; 95% CI: 1.10 to 2.11; p ¼ 0.0117).
To the best of our knowledge, there is no large-scale study that
specifically examined the prevalence of ABI 0.90 in NVAF. In
our population, 21% had ABI 0.90 indicating that NVAF is
often associated with systemic atherosclerosis.
The CHADS2 has been recently refined with the CHA2DS2-
VASc score, which includes vascular disease as documented by
a history of AMI, symptomatic PAD, or detection of atheroscle-
rotic plaque in the aortic arch (4).
Comparison of vascular prevalence as assessed by CHA2DS2-
VASc score and/or ABI 0.90 is of interest to define the poten-
tially positive impact of measuring ABI in the management of
NVAF patients. Inclusion of ABI 0.90 in the definition of
vascular disease greatly increased the prevalence of vascular disease,
which increased from 17.3% (based on history alone) to 33% (based
on ABI) in the entire population. If ABI 0.90 was encompassed
in the definition of vascular disease of CHA2DS2-VASc score the
prevalence of vascular disease increased in every risk class.
Inclusion of ABI0.90 in the CHA2DS2-VASc score allowed us
to better define the risk profile of NVAF patients with an up-grading
of the risk score in each CHA2DS2-VASc score category. This may
have important therapeutic implications if the new score could be
tested prospectively, as a higher number of NVAF patients would
Figure 1 ABI Distribution of Any Category and CHA2DS2-VASc Score Including ABI 0.90
C ¼ congestive heart failure (or left ventricular systolic dysfunction) (Points: 1), H ¼ hypertension (Points: 1), A2 ¼ Age 75 years (Points: 2), D ¼ diabetes mellitus (Points: 1),
S2 ¼ prior stroke or transient ischemic attack or thromboembolism (Points: 2); V ¼ vascular disease (previous acute myocardial infarction, peripheral arterial disease, or aortic
plaque) (Points: 1); A ¼ age 65 to 74 years (Points: 1); Sc ¼ sex category (female) (Points: 1). ABI ¼ ankle brachial index.
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2256potentially be candidates for an anticoagulant treatment by
measuring ABI. A prospective study is, therefore, necessary to
validate the risk score of this new definition of vascular disease.
In conclusion, this study provides the first evidence that one-fifth
of NVAF patients had an ABI 0.90, indicating that it may
represent a simple and cheap method to better define the prevalence
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